ES2949953T3 - Factores genéticos asociados con el desarrollo de inhibidores en hemofilia A - Google Patents
Factores genéticos asociados con el desarrollo de inhibidores en hemofilia A Download PDFInfo
- Publication number
- ES2949953T3 ES2949953T3 ES14154482T ES14154482T ES2949953T3 ES 2949953 T3 ES2949953 T3 ES 2949953T3 ES 14154482 T ES14154482 T ES 14154482T ES 14154482 T ES14154482 T ES 14154482T ES 2949953 T3 ES2949953 T3 ES 2949953T3
- Authority
- ES
- Spain
- Prior art keywords
- individual
- snp
- fviii
- factor viii
- risk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000009292 Hemophilia A Diseases 0.000 title claims description 348
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 title description 268
- 102100026735 Coagulation factor VIII Human genes 0.000 title description 267
- 201000003542 Factor VIII deficiency Diseases 0.000 title description 267
- 239000003112 inhibitor Substances 0.000 title description 31
- 238000011161 development Methods 0.000 title description 22
- 230000002068 genetic effect Effects 0.000 title description 7
- 108010054218 Factor VIII Proteins 0.000 claims abstract description 1522
- 102000001690 Factor VIII Human genes 0.000 claims abstract description 1521
- 229960000301 factor viii Drugs 0.000 claims abstract description 1520
- 238000000034 method Methods 0.000 claims abstract description 1036
- 239000002773 nucleotide Substances 0.000 claims abstract description 50
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 50
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 23
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 18
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 18
- 238000002493 microarray Methods 0.000 claims abstract description 17
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 15
- 238000009007 Diagnostic Kit Methods 0.000 claims abstract description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 662
- 230000003247 decreasing effect Effects 0.000 claims description 304
- 239000012472 biological sample Substances 0.000 claims description 147
- 208000031220 Hemophilia Diseases 0.000 claims description 79
- 229940030225 antihemorrhagics Drugs 0.000 claims description 78
- 239000002874 hemostatic agent Substances 0.000 claims description 78
- 238000011282 treatment Methods 0.000 claims description 61
- 238000012163 sequencing technique Methods 0.000 claims description 31
- 108020004414 DNA Proteins 0.000 claims description 19
- 238000001514 detection method Methods 0.000 claims description 17
- 238000009396 hybridization Methods 0.000 claims description 16
- 238000003556 assay Methods 0.000 claims description 11
- 238000004949 mass spectrometry Methods 0.000 claims description 8
- 238000012175 pyrosequencing Methods 0.000 claims description 8
- 238000003757 reverse transcription PCR Methods 0.000 claims description 8
- 239000007790 solid phase Substances 0.000 claims description 8
- 102000053602 DNA Human genes 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 238000002844 melting Methods 0.000 claims description 7
- 230000008018 melting Effects 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 abstract description 32
- 230000028993 immune response Effects 0.000 abstract description 13
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract description 6
- 102000054765 polymorphisms of proteins Human genes 0.000 abstract description 5
- 239000003550 marker Substances 0.000 description 120
- 238000002648 combination therapy Methods 0.000 description 94
- 230000018109 developmental process Effects 0.000 description 21
- 230000007423 decrease Effects 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 15
- 108010045374 CD36 Antigens Proteins 0.000 description 14
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 14
- 102000049320 CD36 Human genes 0.000 description 13
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 13
- 239000000523 sample Substances 0.000 description 12
- 102100031597 Dedicator of cytokinesis protein 2 Human genes 0.000 description 10
- 101000866237 Homo sapiens Dedicator of cytokinesis protein 2 Proteins 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 108700028369 Alleles Proteins 0.000 description 9
- 102100029057 Coagulation factor XIII A chain Human genes 0.000 description 9
- 101000918352 Homo sapiens Coagulation factor XIII A chain Proteins 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 208000032843 Hemorrhage Diseases 0.000 description 7
- 101000591236 Homo sapiens Receptor-type tyrosine-protein phosphatase R Proteins 0.000 description 7
- 102100034101 Receptor-type tyrosine-protein phosphatase R Human genes 0.000 description 7
- 208000026552 Severe hemophilia A Diseases 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 6
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 6
- 239000003114 blood coagulation factor Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 229940124135 Factor VIII inhibitor Drugs 0.000 description 5
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 5
- 208000034158 bleeding Diseases 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 230000023555 blood coagulation Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 102100022641 Coagulation factor IX Human genes 0.000 description 4
- 108010071289 Factor XIII Proteins 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000006058 immune tolerance Effects 0.000 description 4
- 108010012557 prothrombin complex concentrates Proteins 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000004043 responsiveness Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000033316 Acquired hemophilia A Diseases 0.000 description 3
- 101150061988 DOCK2 gene Proteins 0.000 description 3
- 108010076282 Factor IX Proteins 0.000 description 3
- 108010074864 Factor XI Proteins 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 101100387906 Homo sapiens DOCK2 gene Proteins 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 101150031398 MAPK9 gene Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 108010018823 anti-inhibitor coagulant complex Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229960004222 factor ix Drugs 0.000 description 3
- 229940012444 factor xiii Drugs 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 208000009429 hemophilia B Diseases 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 239000013615 primer Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 102200083281 rs12881815 Human genes 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- -1 Bebulin®-VH Proteins 0.000 description 2
- 101100284398 Bos taurus BoLA-DQB gene Proteins 0.000 description 2
- 101150112561 CD36 gene Proteins 0.000 description 2
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 108010054265 Factor VIIa Proteins 0.000 description 2
- 108010014173 Factor X Proteins 0.000 description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 101150082737 Ptprr gene Proteins 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 208000011664 congenital factor XI deficiency Diseases 0.000 description 2
- 201000007219 factor XI deficiency Diseases 0.000 description 2
- 229940105776 factor viii inhibitor bypassing activity Drugs 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 101150039612 rpsK gene Proteins 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 101150028074 2 gene Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010044217 Class 7 Receptor-Like Protein Tyrosine Phosphatases Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102210012675 DRB1*15 Human genes 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101150019878 F13a1 gene Proteins 0.000 description 1
- 101150104226 F8 gene Proteins 0.000 description 1
- 108010048049 Factor IXa Proteins 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 108700027653 Mitogen-Activated Protein Kinase 9 Proteins 0.000 description 1
- 208000033375 Moderate hemophilia A Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241000206766 Pavlova Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101100407812 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pas4 gene Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000019291 X-linked disease Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940031675 advate Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229940004970 bebulin Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 108090001015 cancer procoagulant Proteins 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229940105778 coagulation factor viii Drugs 0.000 description 1
- 229940105784 coagulation factor xiii Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000021953 cytokinesis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000020287 immunological synapse formation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000012162 pavlova Nutrition 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000008741 proinflammatory signaling process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000004908 prostatic fluid Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000013183 regulation of T cell differentiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32660210P | 2010-04-21 | 2010-04-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2949953T3 true ES2949953T3 (es) | 2023-10-04 |
Family
ID=43983253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14154482T Active ES2949953T3 (es) | 2010-04-21 | 2011-04-21 | Factores genéticos asociados con el desarrollo de inhibidores en hemofilia A |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9637789B2 (https=) |
| EP (2) | EP2730663B1 (https=) |
| JP (4) | JP6058529B2 (https=) |
| AU (1) | AU2011244228B2 (https=) |
| CA (2) | CA2796561C (https=) |
| ES (1) | ES2949953T3 (https=) |
| WO (1) | WO2011131774A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010290131C1 (en) | 2009-08-24 | 2015-12-03 | Amunix Operating Inc. | Coagulation factor VII compositions and methods of making and using same |
| AU2011244228B2 (en) * | 2010-04-21 | 2015-07-30 | Jan Astermark | Genetic factors associated with inhibitor development in hemophilia A |
| BR112014020694A2 (pt) | 2012-02-15 | 2018-05-08 | Amunix Operating Inc. | proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a |
| CA2864126A1 (en) | 2012-02-15 | 2013-08-22 | Biogen Idec Ma Inc. | Recombinant factor viii proteins |
| US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
| BR112018002150A2 (pt) | 2015-08-03 | 2018-09-18 | Bioverativ Therapeutics Inc | proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas |
| KR101774996B1 (ko) * | 2016-06-23 | 2017-09-19 | 주식회사 녹십자지놈 | 혈우병 치료제의 효능 예측 마커 및 이의 용도 |
| IL319473A (en) | 2016-12-02 | 2025-05-01 | Bioverativ Therapeutics Inc | Methods for treating hemophilic arthritis using chimeric blood clotting factors |
| BR112020022164A2 (pt) | 2018-05-18 | 2021-02-02 | Bioverativ Therapeutics Inc. | métodos de tratamento de hemofilia a |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| JP4071277B2 (ja) | 1993-11-12 | 2008-04-02 | ピーエイチアールアイ・プロパティーズ・インコーポレーテッド | 核酸検出用ハイブリダイゼーションプローブ、共通ステム、方法およびキット |
| AU710425B2 (en) | 1995-12-18 | 1999-09-23 | Washington University | Method for nucleic acid analysis using fluorescence resonance energy transfer |
| WO2008059009A2 (en) * | 2006-11-16 | 2008-05-22 | Crucell Holland B.V. | Factor v mutants for hemostasis in hemophilia |
| AU2011244228B2 (en) * | 2010-04-21 | 2015-07-30 | Jan Astermark | Genetic factors associated with inhibitor development in hemophilia A |
-
2011
- 2011-04-21 AU AU2011244228A patent/AU2011244228B2/en active Active
- 2011-04-21 CA CA2796561A patent/CA2796561C/en active Active
- 2011-04-21 EP EP14154482.5A patent/EP2730663B1/en active Active
- 2011-04-21 US US13/091,968 patent/US9637789B2/en active Active
- 2011-04-21 ES ES14154482T patent/ES2949953T3/es active Active
- 2011-04-21 CA CA3050896A patent/CA3050896C/en active Active
- 2011-04-21 WO PCT/EP2011/056471 patent/WO2011131774A1/en not_active Ceased
- 2011-04-21 JP JP2013505490A patent/JP6058529B2/ja active Active
- 2011-04-21 EP EP11715562A patent/EP2561090A1/en not_active Withdrawn
- 2011-08-10 US US13/207,286 patent/US9644239B2/en active Active
-
2015
- 2015-09-16 JP JP2015183020A patent/JP6189904B2/ja active Active
-
2017
- 2017-03-14 US US15/458,878 patent/US20180016635A1/en not_active Abandoned
- 2017-08-03 JP JP2017151073A patent/JP6568162B2/ja active Active
-
2019
- 2019-08-01 JP JP2019142337A patent/JP2019180421A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US9644239B2 (en) | 2017-05-09 |
| CA3050896A1 (en) | 2011-10-27 |
| EP2730663A3 (en) | 2014-09-10 |
| EP2730663B1 (en) | 2023-03-22 |
| JP2019180421A (ja) | 2019-10-24 |
| AU2011244228B2 (en) | 2015-07-30 |
| US20120065077A1 (en) | 2012-03-15 |
| AU2011244228A1 (en) | 2012-11-08 |
| CA2796561A1 (en) | 2011-10-27 |
| CA3050896C (en) | 2023-01-24 |
| JP2015226551A (ja) | 2015-12-17 |
| JP6189904B2 (ja) | 2017-08-30 |
| EP2730663A2 (en) | 2014-05-14 |
| JP6568162B2 (ja) | 2019-08-28 |
| US9637789B2 (en) | 2017-05-02 |
| US20180016635A1 (en) | 2018-01-18 |
| JP2013529071A (ja) | 2013-07-18 |
| JP6058529B2 (ja) | 2017-01-11 |
| JP2017200491A (ja) | 2017-11-09 |
| EP2561090A1 (en) | 2013-02-27 |
| CA2796561C (en) | 2019-09-17 |
| WO2011131774A1 (en) | 2011-10-27 |
| US20110312519A1 (en) | 2011-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2949953T3 (es) | Factores genéticos asociados con el desarrollo de inhibidores en hemofilia A | |
| Mostowska et al. | Association between genetic variants of reported candidate genes or regions and risk of cleft lip with or without cleft palate in the polish population | |
| ES2660818T3 (es) | Marcadores genéticos para predecir la capacidad de respuesta a un compuesto de FGF-18 | |
| Aldhorae et al. | Nonsyndromic cleft lip with or without cleft palate in arab populations: Genetic analysis of 15 risk loci in a novel case–control sample recruited in Yemen | |
| CN104755629A (zh) | 软骨疾病的预后生物标记 | |
| US20130035314A1 (en) | Methods and kits for detecting risk factors for development of jaw osteonecrosis and methods of treatment thereof | |
| CN107849041B (zh) | 与对crth2受体拮抗剂的反应有关的遗传标记 | |
| KR102443042B1 (ko) | 직접경구용 항응고제 투여시의 출혈 부작용 예측용 snp 마커 및 이의 용도 | |
| AU2015249180B2 (en) | Genetic factors associated with inhibitor development in hemophilia a | |
| JP6017117B2 (ja) | 炎症性腸疾患患者におけるアザチオプリン（ａｚｔ）の血中濃度の安定性を予測するジェネティックバイオマーカー | |
| JP4979382B2 (ja) | 薬剤誘発肝細胞毒性を予測するための遺伝子多型の使用 | |
| HK1197923B (en) | Genetic factors associated with inhibitor development in hemophilia a | |
| HK1197923A (en) | Genetic factors associated with inhibitor development in hemophilia a | |
| KR101782227B1 (ko) | 시나칼셋 반응성과 연관된 casr 유전자의 단일뉴클레오타이드 다형성 마커 및 그 용도 | |
| KR20230150127A (ko) | 심근경색과 연관된 유전자 다형성 및 그의 용도 | |
| US9150925B1 (en) | SNP panels for predicting prostate cancer-specific mortality | |
| WO2019140517A1 (en) | Method of use of ykl-40 in scoliosis | |
| JP2009207448A (ja) | 自己免疫疾患の検査方法及び自己免疫疾患の予防又は治療薬のスクリーニング方法 |